Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes
Authors' conclusion
Baseline levels of two plasma sphingolipid species are independent predictors of AF development in patients with T2D. These findings could help identify T2D patients at elevated risk of adverse hepatic and extrahepatic outcomes, potentially allowing for new targeted therapeutic interventions.
Study context
- Population
- Patients with T2D; baseline plasma concentrations of 148 molecular species of phospholipids, sphingolipids and free fatty acids
- Participants
- 67 patients
- Outcome
- Development of advanced liver fibrosis (AF): liver stiffness ≥8.0 kPa, or ultrasonographic signs of cirrhosis
- Follow-up
- Mean 10.2 ± 3.9 years
Methodological detailslipidomic biomarker study, machine-learning multivariate analysis
- Lipidomic biomarker study
- Machine-learning multivariate analysis
Main finding
As reported in the abstract
Development of AF · follow-up period
AF developed
14 patients
20.9%
Observational data: associations, not effects.
Original publication
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes. Diabetes Obes Metab. Published 24 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →